Bio

Dr. Shah is a fellowship-trained urologic oncologist specializing in the treatment of bladder cancer and other urologic cancers. He has a special interest in robotic surgery, emerging treatment options, and optimization of post-surgical recovery. Having written many peer-reviewed papers and book chapters on these topics, he is a well-respected authority in his field. He takes tremendous pride in getting to know every patient and helping them choose the treatment plan that is right for them.

Prior to joining the Stanford Cancer Center, Dr. Shah was on faculty at MD Anderson Cancer Center for seven years where he served as Center Medical Director of the Genitourinary Center as well as Director of the Bladder Cancer Robotics Program and supervisor of Medical Student Education for the Department of Urology.

Clinical Focus

  • Urology

Academic Appointments

  • Associate Professor - Med Center Line, Urology

Administrative Appointments

  • Genitourinary Cancer Care Program Leader, Stanford Cancer Center (2017 - Present)
  • Center Medical Director, MDACC Genitourinary Center (2016 - 2016)
  • Member, American Urological Association International Academic Fellowship Committee (2015 - Present)
  • Director, MDACC Bladder Cancer Robotics Program (2014 - 2016)
  • Co-Quality Improvement Officer, MDCC Department of Urology (2014 - 2016)
  • Supervisor, MDACC Department of Urology Journal Club (2012 - 2015)
  • Director, MDACC Department of Urology Medical Student Education (2010 - 2015)

Honors & Awards

  • Faculty Leadership Academy, MD Anderson Cancer Center (2016-2017)
  • Leadership Academy, American Urological Association (2016-2017)
  • Clinical Innovator Award, MD Anderson Cancer Center (2015-2017)
  • Genitourinary SPORE Career Development Award, MD Anderson Cancer Center (2014-2016)
  • Comparative Effectiveness Research on Cancer, Texas Scholar Award (2012-2014)
  • Gold Humanism Honor Society Inductee, Gold Foundation (2006)
  • Gerald P. Murphy Scholar, Ford Library and Museum (2006)
  • Humanism and Excellence in Teaching Award, Arnold P. Gold Foundation (2006)

Professional Education

  • Master’s Degree, UT-Houston Medical School, Houston, TX, Clinical Investigation (2016)
  • Healthcare Course, Harvard Business School Extension Program, Cambridge, MA, Value Measurement (2015)
  • Urologic Oncology Fellowship, MD Anderson Cancer Center, Houston, TX (2010)
  • Board Certification: Urology, American Board of Urology (2012)
  • Urology Chief Residency, Columbia University Medical Center, New York, NY (2007)
  • Fellowship:MD Anderson Cancer Center Urologic Oncology (2010) TX
  • Urology Residency, Columbia University Medical Center, New York, NY (2006)
  • Residency:Columbia University Medical Center (2007) NY
  • General Surgery Internship, Columbia University Medical Center, New York, NY (2003)
  • Internship:New York Presbyterian Surgery Residency (2003) NY
  • Doctorate in Medicine, Columbia College of Physicians & Surgeons, New York, NY (2002)
  • Medical Education:Columbia University College of Physicians and Surgeons (2002) NY
  • BA in Biological Sciences, Harvard College, Cambridge, MA (1998)

Contact

  • University - Faculty Department: Urology - Divisions Position: Assoc Prof-Med Ctr Line
  • Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr Rm 2217 MC 6560 Stanford, CA 94305 (650) 736-8003 (fax)

Additional Info

  • Mail Code: 6567

All Publications

  • Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design EUROPEAN UROLOGY Mmeje, C. O., Guo, C. C., Shah, J. B., Navai, N., Grossman, H. B., Dinney, C. P., Kamat, A. M. 2016; 70 (5): 778-785

    Abstract

    Recurrence with papillary tumor(s) by 3-mo after induction bacillus Calmette-Guérin (BCG) is historically believed to be a poor prognostic indicator in patients with high-risk non-muscle invasive bladder cancer. However, the impact of a clinical Ta (cTa) papillary recurrence at 3 mo after BCG is often debated.To evaluate the prognostic implications of cTa papillary recurrence found 3 mo after induction BCG therapy and to evaluate its significance in clinical trial design.We reviewed our database of 917 patients who underwent transurethral resection and induction of BCG from 1995 to 2012. Clinical characteristics were compared between 3-mo recurrence stages.Transurethral resection of bladder tumor and intravesical therapy.Chi-square analysis and Student t test were used to compare clinical characteristics between 3-mo recurrence stages. Kaplan-Meier method was used to determine bladder-preservation time, progression-free survival, and disease-specific survival.We identified 84 patients who met the study criteria (66 patients with cTa and 18 patients with clinical T1 [cT1]). The median follow-up for the entire cohort was 74 mo. Of the patients with cTa recurrence, 60 continued with bladder-sparing therapy. Patients with a high-grade cTa recurrence who continued bladder-sparing therapy had a 17% incidence of disease progression and a 62% incidence of recurrence within 1 yr. No patients with low-grade cTa recurrence (n=13) developed disease progression or underwent radical cystectomy. Patients with an initial cTa at diagnosis had a higher 5-yr bladder preservation rate than those with an initial cT1 diagnosis (84% vs 61%; p=0.041). Patients with high-grade cTa recurrence and those with cT1 recurrence had similar outcomes with respect to death rates over the entire follow-up period (11% and 15%, respectively), as well as 5-yr progression-free survival (77% vs 83%). Limitations include using a single institution and a retrospective review.Patients with low-grade cTa papillary recurrence 3 mo after induction of BCG can safely continue with bladder-sparing therapy. Patients with high-grade cTa papillary recurrence at that time have risks of recurrence and progression similar to those of patients with cT1 recurrence. These are important factors to consider during clinical trial design.Low-grade clinical Ta papillary recurrence following induction of bacillus Calmette-Guérin therapy can be safely managed conservatively, although a high-grade clinical Ta recurrence should be treated similar to a clinical T1 recurrence due to its comparable progression rates.

    View details for DOI 10.1016/j.eururo.2016.02.031

    View details for Web of Science ID 000385515600020

    View details for PubMedID 26922408

  • Association between Perioperative Blood Transfusions and Clinical Outcomes in Patients Undergoing Bladder Cancer Surgery: A Systematic Review and Meta-Analysis Study. Journal of blood transfusion Cata, J. P., Lasala, J., Pratt, G., Feng, L., Shah, J. B. 2016; 2016: 9876394-?

    Abstract

    Background. Perioperative blood transfusions are associated with poor survival in patients with solid tumors including bladder cancer. Objective. To investigate the impact of perioperative blood transfusions on oncological outcomes after radical cystectomy. Design. Systematic review and meta-analysis. Setting and Participants. Adult patients who underwent radical cystectomy for bladder cancer. Intervention. Packed red blood cells transfusion during or after radical cystectomy for bladder cancer. Outcome Measurements and Statistical Analysis. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). We calculated the pooled hazard ratio (HR) estimates and 95% confidence intervals by random and fixed effects models. Results and Limitation. Eight, seven, and five studies were included in the OS, CSS, and RFS analysis, respectively. Blood transfusions were associated with 27%, 29%, and 12% reduction in OS, CSS, and RFS, respectively. A sensitivity analysis supported the association. This study has several limitations; however the main problem is that it included only retrospective studies. Conclusions. Perioperative BT may be associated with reduced RFS, CSS, and OS in patients undergoing RC for BC. A randomized controlled study is needed to determine the causality between the administration of blood transfusions and bladder cancer recurrence.

    View details for DOI 10.1155/2016/9876394

    View details for PubMedID 26942040